Cardiovascular Specific Gene Expression

  • Pieter A. Doevendans
  • Robert S. Reneman
  • Marc van Bilsen

Part of the Developments in Cardiovascular Medicine book series (DICM, volume 214)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Cardiology Approaching the Year 2000. A Clinician’s Look at Molecular Cardiology

  3. Cardiovascular specific gene expression

    1. Diego Franco, Robert Kelly, Peter Zammit, Margaret Buckingham, Antoon F. M. Moorman
      Pages 7-16
    2. Stefano Schiaffino, Simonetta Ausoni, Caterina Millino, Elisa Calabria, Claudia Sandri, Raffaella Di Lisi
      Pages 17-25
    3. Guillaume J. J. M. van Eys, Carlie J. M. de Vries, Sander S. M. Rensen, Victor L. J. L. Thijssen, Edward L. C. Verkaar, Gisela P. G. M. Coolen et al.
      Pages 49-66
  4. Transcription regulation

    1. Robert G. Kelly, Peter S. Zammit, Diego Franco, Antoon F. M. Moorman, Margaret E. Buckingham
      Pages 67-73
    2. Paul J. R. Barton, Pankaj K. Bhavsar, Kimberley A. Dellow, Philip J. Townsend, Magdi H. Yacoub, Nigel J. Brand
      Pages 75-86
    3. Pilar Ruiz-Lozano, Kenneth R. Chien
      Pages 87-97
    4. Pieter A. Doevendans, Ronald Bronsaer, Pilar Ruiz-Lozano, Jan Melle van Dantzig, Marc van Bilsen
      Pages 99-116
    5. W. Antoinette Groenewegen
      Pages 117-124
  5. Ion channels and gap junction

    1. Anne-Marie Lompré, Olivier Vallot, Marielle Anger, Anne Ozog
      Pages 139-150
    2. Connie Alshinawi, Arthur A. M. Wilde
      Pages 151-160
    3. Jacques-Antoine Haefliger, Paolo Meda
      Pages 161-169
    4. Andrew A. Grace, Richard C. Saumarez, Jamie I. Vandenberg
      Pages 171-178
  6. Intracellular signaling

    1. Thomas I. Koblizek, Werner Risau, Urban Deutsch
      Pages 179-191
    2. Peter Carmeliet, Désiré Collen
      Pages 193-225

About this book

Introduction

Improving our insights into the genetic predisposition to cardiovascular disease is one of the most important challenges in our field in the next millennium, not only to unravel the cause of disease but also to improve the selection of patients for particular treatments. Nowadays, for example, subjects with a cholesterol above a particular plasma level are exposed to a cholesterol lowering regime based upon the beneficial outcome of epidemiological studies which include subjects not prone to the disease, despite a plasma cholesterol above the accepted level. Identification of the patients who are genetically predisposed to the consequences of this disorder will reduce the number of subjects unnecessarily treated and, hence, the costs of health care. Because in most cardiovascular diseases the genetic component is a consequence of more than one gene defect, only limited progress has as yet been made in identifying subjects genetically at risk. For example, in hypertension only in less than 10% of the patients the genetic defect has been identified. It has been known for quite some time that in heart and blood vessels fetal genes are as high blood pressure and upregulated or induced when they are exposed to such disorders ischemia. Little is known about the function of these genes in the cardiac and vascular adaptation to these disorders; only guesses can be made.

Keywords

Chromosom Promoter cardiovascular cardiovascular system development gene expression gene therapy genes heart membrane phenotype physiology tissue transcription vascular disease

Editors and affiliations

  • Pieter A. Doevendans
    • 1
  • Robert S. Reneman
    • 2
  • Marc van Bilsen
    • 3
  1. 1.Department of CardiologyAcademic Hospital MaastrichtMaastrichtThe Netherlands
  2. 2.Academic Hospital MaastrichtCARIMMaastrichtThe Netherlands
  3. 3.Department of PhysiologyAcademic Hospital MaastrichtMaastrichtThe Netherlands

Bibliographic information

  • DOI https://doi.org/10.1007/978-94-015-9321-2
  • Copyright Information Springer Science+Business Media B.V. 1999
  • Publisher Name Springer, Dordrecht
  • eBook Packages Springer Book Archive
  • Print ISBN 978-90-481-5189-9
  • Online ISBN 978-94-015-9321-2
  • Series Print ISSN 0166-9842
  • About this book
Industry Sectors
Biotechnology
Pharma